Provided herein are anti-fibrotic compounds, in particular those of Formula (I), that inhibit the TGF-beta signaling pathway. Also provided are pharmaceutical compositions comprising the anti-fibrotic compounds, and methods of treating diseases or conditions associated with fibrosis, inflammation, and benign or malignant neoplastic diseases in a subject by administering a compound or composition described herein.

Provided herein are anti-fibrotic compounds, in particular those of Formula (I), that inhibit the TGF-beta signaling pathway. Also provided are pharmaceutical compositions comprising the anti-fibrotic compounds, and methods of treating diseases or conditions associated with fibrosis, inflammation, and benign or malignant neoplastic diseases in a subject by administering a compound or composition described herein.

Described herein are compounds that disrupt the interaction between Fbxo48 and phosphorylated-AMPK.

Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof (I). Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

##STR00001##

Provided herein are anti-fibrotic compounds, in particular those of Formula (I), that inhibit the TGF-beta signaling pathway. Also provided are pharmaceutical compositions comprising the anti-fibrotic compounds, and methods of treating diseases or conditions associated with fibrosis, inflammation, and benign or malignant neoplastic diseases in a subject by administering a compound or composition described herein. (Formula (I))

Provided herein are anti-fibrotic compounds, in particular those of Formula (I), that inhibit the TGF-beta signaling pathway. Also provided are pharmaceutical compositions comprising the anti-fibrotic compounds, and methods of treating diseases or conditions associated with fibrosis, inflammation, and benign or malignant neoplastic diseases in a subject by administering a compound or composition described herein. (Formula (I))

A corrosion inhibiting compound with a general structure A-B or A-X-B for inhibition of corrosion of steel in acidic solution. A comprises a heterocyclic ring system having a plurality of cyclic Carbon atoms and at least one cyclic Nitrogen atom, wherein the at least one cyclic Nitrogen atom is neutral under neutral conditions and protonatable under acidic conditions. B comprises at least two unsaturated Carbon atoms. B may comprise a ring system or a polymerisable group.

A corrosion inhibiting compound with a general structure A-B or A-X-B for inhibition of corrosion of steel in acidic solution. A comprises a heterocyclic ring system having a plurality of cyclic Carbon atoms and at least one cyclic Nitrogen atom, wherein the at least one cyclic Nitrogen atom is neutral under neutral conditions and protonatable under acidic conditions. B comprises at least two unsaturated Carbon atoms. B may comprise a ring system or a polymerisable group.

Provided are compounds of Formula (I): and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with histone acetyltransferase (HAT).

##STR00001##

Provided are compounds of Formula (I): and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with histone acetyltransferase (HAT).

##STR00001##